US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SPCX $158.96 ▲+0.00% SDEV $7.48 ▲+0.00% AMD $633.91 ▲+0.00% TSLA $370.59 ▲+0.00%
FinancialContent

Articles published by MaxCyte, Inc

< Previous 1 2 Next >
News headline image
MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
News headline image
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
News headline image
MaxCyte Announces Retirement of Board Member Art Mandell
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
News headline image
MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
News headline image
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
News headline image
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
News headline image
MaxCyte to Participate in Two Upcoming Investor Conferences
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
News headline image
MaxCyte Appoints Cynthia Collins to its Board of Directors
From MaxCyte, Inc
Via GlobeNewswire
Tickers CERT DMTKQ MXCT PSTX
News headline image
MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
News headline image
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
News headline image
MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
News headline image
MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
News headline image
MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
News headline image
MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
News headline image
MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
News headline image
MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
News headline image
MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
News headline image
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
News headline image
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
News headline image
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
News headline image
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
News headline image
MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
News headline image
MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
News headline image
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
From MaxCyte, Inc
Via GlobeNewswire
Tickers ASX:IMU MXCT
News headline image
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
News headline image
MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
News headline image
MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
News headline image
MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
News headline image
MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
News headline image
MaxCyte to Participate in Two Upcoming Investor Conferences
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
< Previous 1 2 Next >